title: Arginine vasopressin-mediated cardiac differentiation: insights into the role of its receptors and nitric oxide signaling.
abstract: Despite the existence of a functional arginine vasopressin (AVP) system in the adult heart and evidence that AVP induces myogenesis, its significance in cardiomyogenesis is currently unknown. In the present study, we hypothesized a role for AVP in cardiac differentiation of D3 and lineage-specific embryonic stem (ES) cells expressing green fluorescent protein under the control of atrial natriuretic peptide (Anp) or myosin light chain-2V (Mlc-2V) promoters. Furthermore, we investigated the nitric oxide (NO) involvement in AVP-mediated pathways. AVP exposure increased the number of beating embryoid bodies, fluorescent cells, and expression of Gata-4 and other cardiac genes. V1a and V2 receptors (V1aR and V2R) differentially mediated these effects in transgenic ES cells, and exhibited a distinct developmentally regulated mRNA expression pattern. A NO synthase inhibitor, L-NAME, powerfully antagonized the AVP-induced effects on cardiogenic differentiation, implicating NO signaling in AVP-mediated pathways. Indeed, AVP elevated the mRNA and protein levels of endothelial NO synthase (eNOS) through V2R stimulation. Remarkably, increased beating activity was found in AVP-treated ES cells with down-regulated eNOS expression, indicating the significant involvement of additional pathways in cardiomyogenic effects of AVP. Finally, patch clamp recordings revealed specific AVP-induced changes of action potentials and increased L-type Ca2+ (ICa,L) current densities in differentiated ventricular phenotypes. Thus, AVP promotes cardiomyocyte differentiation of ES cells and involves Gata-4 and NO signaling. AVP-induced action potential prolongation appears likely to be linked to the increased ICa,L current in ventricular cells. In conclusion, this report provides new evidence for the essential role of the AVP system in ES cell-derived cardiomyogenesis.
authors.affiliation: Department of Internal Medicine III, University of Cologne, 50924 Cologne, Germany.
authors.forename: Natig
authors.initials: N
authors.lastname: Gassanov
authors.forename: Marek
authors.initials: M
authors.lastname: Jankowski
authors.forename: Bogdan
authors.initials: B
authors.lastname: Danalache
authors.forename: Donghao
authors.initials: D
authors.lastname: Wang
authors.forename: Ryszard
authors.initials: R
authors.lastname: Grygorczyk
authors.forename: Uta C
authors.initials: UC
authors.lastname: Hoppe
authors.forename: Jolanta
authors.initials: J
authors.lastname: Gutkowska
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism*; D002454:Cell Differentiation; D002478:Cells, Cultured; D004594:Electrophysiology; D005786:Gene Expression Regulation; D051379:Mice; D009206:Myocardium / Q000166:cytology* / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism; D018408:Patch-Clamp Techniques; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D017483:Receptors, Vasopressin / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D012333:RNA, Messenger; D034741:RNA, Small Interfering; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III